AEMD Share Price | Aethlon Medical, Inc. Stock Analysis & Recommendation

Q: What does Aethlon Medical, Inc. do?

Overview: Aethlon Medical, Inc. is a medical device company focused on creating devices for cancer, infectious disease, and other life-threatening conditions, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.Financial Snapshot: Most recent Net Profit: -2 Million (Quarterly Results - Dec 2024) Market cap: USD 3.56 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.04 Return on Equity: -220.54% Price to Book: 0.82Contact Details: Address: 9635 Granite Ridge Dr Ste 100, SAN DIEGO CA: 92123 Tel: 1 858 4597800 Website: https://www.aethlonmedical.com/

Q: Is Aethlon Medical, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Aethlon Medical, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish, with key indicators driving this conclusion including a bearish daily moving average and a bearish monthly Bollinger Band. Although the MACD shows mildly bullish signals on both weekly and monthly time frames, the overall sentiment is dampened by the bearish Dow Theory and the lack of trend in the On-Balance Volume (OBV). In terms of performance, Aethlon Medical has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -88.66% compared to the S&P 500's 12.22%, and a staggering 10-year return of -99.32% versus the S&P 500's 231.64%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

11.11 k

Shareholding (Sep 2025)

FII

1.11%

Held by 5 FIIs

DII

98.19%

Held by 1 DIIs

Promoter

0.00%

How big is Aethlon Medical, Inc.?

22-Jun-2025

As of Jun 18, Aethlon Medical, Inc. has a market capitalization of 3.56 million and reported net sales of 0.00 million with a net profit of -9.56 million over the last four quarters. Shareholder's funds were 5.77 million, and total assets were 8.25 million.

View full answer

What does Aethlon Medical, Inc. do?

22-Jun-2025

Aethlon Medical, Inc. is a micro-cap medical device company focused on developing devices for cancer and infectious diseases. As of December 2024, it has a market cap of $3.56 million and reported a net profit loss of $2 million.

View full answer

Who are in the management team of Aethlon Medical, Inc.?

22-Jun-2025

As of March 2022, the management team of Aethlon Medical, Inc. includes Mr. Edward Broenniman (Chairman of the Board), Ms. Sabrina Johnson (Independent Director), and Dr. Chetan Shah (Independent Director).

View full answer

Is Aethlon Medical, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Aethlon Medical, Inc. is in a bearish trend, indicated by a bearish daily moving average and monthly Bollinger Band, despite some mildly bullish MACD signals, and has significantly underperformed the S&P 500 with a year-to-date return of -88.66%.

View full answer

Compare Aethlon Medical, Inc. with Similar Stocks

NeuroMetrix, Inc.Sharps Technology, Inc.Creative Medical Technology Holdings, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 2 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.86%

Debt Equity

-0.95

Return on Equity

-115.66%

Price to Book

0.37

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-32.41%

6 Months

-26.45%

1 Year

-50.27%

2 Years

-92.04%

3 Years

-97.51%

4 Years

-99.6%

5 Years

-98.06%

Aethlon Medical, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-17.59%

EBIT Growth (5y)

-12.09%

EBIT to Interest (avg)

-9.18

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.98

Sales to Capital Employed (avg)

0.06

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

19.77%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.22

EV to EBIT

-0.08

EV to EBITDA

-0.08

EV to Capital Employed

-0.79

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-220.54%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 2 Schemes (0.7%)

Foreign Institutions

Held by 5 Foreign Institutions (1.11%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Jun 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 16.67% vs 71.43% in Jun 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.40",
          "val2": "-1.60",
          "chgp": "12.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.50",
          "val2": "-1.80",
          "chgp": "16.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 0.00% vs -100.00% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is -9.84% vs -1.67% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.00",
          "val2": "-12.30",
          "chgp": "26.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.60",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.40",
          "val2": "-12.20",
          "chgp": "-9.84%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Sep'25

Jun'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-1.40

-1.60

12.50%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-1.50

-1.80

16.67%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Jun 2025

Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is 16.67% vs 71.43% in Jun 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Mar'25

Mar'25

Mar'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-9.00

-12.30

26.83%

Interest

0.00

Exceptional Items

-4.60

0.00

Consolidate Net Profit

-13.40

-12.20

-9.84%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2025 is 0.00% vs -100.00% in Mar 2024

Consolidated Net Profit

YoY Growth in year ended Mar 2025 is -9.84% vs -1.67% in Mar 2024

All Annual Results

Company CV

About Aethlon Medical, Inc.

Aethlon Medical, Inc.

Pharmaceuticals & Biotechnology

Aethlon Medical, Inc. is a medical device company focused on creating devices for cancer, infectious disease and other life-threatening conditions. The Company operates through two segments: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities. The Company's lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The Aethlon Hemopurifier sheds glycoproteins to treat infectious viral pathogens. In oncology indications, the Hemopurifier targets the removal of circulating exosomes, which are released to promote cancer progression and to seed the spread of metastasis. Through its subsidiary, Exosome Sciences, Inc. (Exosome), the Company is also developing exosome-based product candidates to diagnose and monitor neurological disorders and cancer.

Company Coordinates

Company Details

9635 Granite Ridge Dr Ste 100 , SAN DIEGO CA : 92123

Tel: 1 858 4597800

https://www.aethlonmedical.com/

Registrar Details

Aethlon Medical, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Aethlon Medical, Inc.?

Watch in Real-Time

What does Aethlon Medical, Inc. do?

Who are in the management team of Aethlon Medical, Inc.?

Is Aethlon Medical, Inc. technically bullish or bearish?

Compare Aethlon Medical, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Annual Results Snapshot (Consolidated) - Mar'25

About Aethlon Medical, Inc.

Company Coordinates